BioAge Labs, Inc. - Common Stock (NQ:BIOA)

8.650 +0.060 (+0.70%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Volume	190,390
Open	8.590
Bid (Size)	8.100 (400)
Ask (Size)	9.000 (300)
Prev. Close	8.590
Today's Range	8.440 - 8.990
52wk Range	2.880 - 20.37
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

November 07, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat ↗

November 06, 2025

BioAge Labs reported a mixed Q3 2025, beating revenue estimates by 94% with a narrower EPS loss. The clinical-stage biotech advanced its lead drug, BGE-102, with cash runway through 2029.

Via Chartmill

Performance

YTD	+55.6%	+55.6%
1 Month	+13.8%	+13.8%
3 Month	+91.8%	+91.8%
6 Month	+119.0%	+119.0%
1 Year	-54.6%	-54.6%

More News

BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 06, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗

November 05, 2025

Via The Motley Fool

Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗

October 29, 2025

Via The Motley Fool

BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗

October 26, 2025

Via The Motley Fool

Here are the top movers in Thursday's session. ↗

October 23, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 23, 2025

Via Benzinga

Which stocks are moving on Thursday? ↗

October 23, 2025

Via Chartmill

These stocks are gapping in today's session ↗

October 23, 2025

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

October 23, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 23, 2025

Via Benzinga

This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗

October 22, 2025

Via Benzinga

BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 02, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

BioAge Labs to Present at Upcoming Investor Conferences

August 20, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

August 15, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs (BIOA) Q2 Revenue Hits $2.4M ↗

August 06, 2025

Via The Motley Fool

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 06, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 02, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

June 21, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

June 17, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

June 03, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

May 29, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs to Present at Upcoming Investor Conferences

May 27, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 21, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is BioAge Labs, Inc. - Common Stock publicly traded?

Yes, BioAge Labs, Inc. - Common Stock is publicly traded.

What exchange does BioAge Labs, Inc. - Common Stock trade on?

BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BioAge Labs, Inc. - Common Stock?

The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market

What is the current price of BioAge Labs, Inc. - Common Stock?

The current price of BioAge Labs, Inc. - Common Stock is 8.650

When was BioAge Labs, Inc. - Common Stock last traded?

The last trade of BioAge Labs, Inc. - Common Stock was at 11/21/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.